摘要
目的探讨生物共振治疗系统联合氯雷他定治疗变应性鼻炎的临床疗效及安全性。方法将患者分为3组,仪器组65例,采用生物共振治疗系统进行脱敏治疗;药物组61例口服氯雷他定10mg,1次/d,连续用3周;联合治疗组46例,采用生物共振治疗系统脱敏治疗同时口服氯雷他定10mg,1次/d,连续用3周。结果 3组有效率差异有统计学意义(P<0.05),仪器组与药物组有效率比较差异无统计学意义(P>0.05)。3组复发率比较差异有统计学意义(P<0.01)。结论生物共振治疗系统联合氯雷他定治疗变应性鼻炎可提高疗效,且复发率低。
Objective To determine the clinical efficacy and safety of bicom- bioresonace therapy and loratadine in patients with allergic rhinitis. Methods The patients were divided into three groups. The first group （65 cases） were treated with bicom- bioresonace therapy alone ,the second group （61 cases） with loratadine 10mg daily for three weeks and the third group （46 cases） with the combination of the two therapies. Results There were significant differences in effective rate among the three groups （P 〈 0.05 ）, of which the third group had significant difference as compared with the first and the second groups （ P 〈 0.05 ）. The difference did not reach the statistically significant level between the first and the second groups （ P 〉 0.05 ）. There were statistically significant differences between the three groups （P 〈 0.01 ） in the recurrence rate. Conclusion Bicom - bioresonace therapy was useful in the treatment of allergic rhinitis with few side effects and low recurrence rate. Especially, the combination with loratadine therapy can improve the clinical efficacy.
出处
《河北医科大学学报》
CAS
2011年第12期1402-1404,共3页
Journal of Hebei Medical University
关键词
鼻炎
变应性
常年性
生物共振
氯雷他定
rhinitis, allergic, perennial
bicom - bioresonacetherapy
loratadine
